Schizophrenia Treatment
Market: Novel Products to Provide Slight Boost by 2022, While Unmet Needs
Remain, says Publisher
The global schizophrenia
treatment market value is expected to undergo a modest increase over the coming
decade, climbing from $6.3 billion in 2012 to $7.9 billion by 2022, at a
Compound Annual Growth Rate (CAGR) of 2.4%, according to a new report from
research and consulting firm by Publisher.
The company’s latest report*
states that out of the seven major markets (7MM: the US, France, Germany,
Italy, Spain, the UK and Japan), the US dominated the schizophrenia space in
2012 with sales of $5.2 billion and a global share of 83%. It will maintain its
market-leading position by 2022 with sales of $6.1 billion, representing a CAGR
of 1.6% during the forecast period.
Publisher attributes the
anticipated market expansion to a rising awareness of mental health, along with
increasing utilization of long-acting injectable (LAI) antipsychotics and
various new product launches.
Among the drugs that are due
to enter the market during the forecast period are Otsuka’s brexpiprazole,
Roche/Chugai’s bitopertin, EnVivo’s EVP-6124 and Alkermes’ aripiprazole lauroxil
and Invega Sustenna (Three-Month).
According to
Analyst covering Neurology, “These latter two drugs will introduce new
LAI treatments and expand the global market options by 33%. The three-month
version of Pfizer’s Invega Sustenna in particular will provide patients with a
reduced dosing burden.
“As novel products in an
emerging part of the schizophrenia drug market, these agents could be met with
significant sales, due to their higher costs of therapy and a growing
popularity of LAIs in this space.”
However, such costs may well
push patients toward generic alternatives, subsequently hindering any further
growth in the global schizophrenia market, according to Publisher.
Furthermore, the level of
unmet need in schizophrenia and related mental health disorders is one of the
highest in medicine today, presenting another significant barrier to the
market.
According to
Analyst, “Schizophrenia treatment currently consists of first-generation
antipsychotics and atypical therapies, which do not adequately satisfy
patients’ needs.
“While the pipeline boasts
several candidates targeting negative and cognitive symptoms, in addition to a
number of LAI therapies, the fierce competition surrounding the schizophrenia
market means these products will have to demonstrate that their utility
surpasses those of currently marketed options,” the analyst concludes.
PharmaPoint: Schizophrenia -
Global Drug Forecast and Market Analysis to 2022 report provides an overview of
schizophrenia, including etiology, general symptoms and country-specific
treatment recommendations and compliance data. The key topics covered include
strategic competitor assessment, market characterization, unmet needs, clinical
trial mapping and implications for the schizophrenia market.
This report was built using
data and information sourced from proprietary databases, primary and secondary
research, and in-house analysis conducted by Publisher’s team of industry
experts.
Know
more about this report at: http://mrr.cm/ZqT
Find all Pharma and Healthcare Reports at : http://www.marketresearchreports.com/pharma-healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.